Decitabine treatment of patients with higher-risk myelodysplastic syndromes

Leukemia Research

Volumn 33, Issue SUPPL. 2, 2009, Pages

  Steensma, David P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

5 Aza 2 deoxycytidine; Azacitidine; Clinical trials; DNA methylation Decitabine; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR;

ANEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOPENIA; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; UNITED STATES;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CLINICAL TRIALS AS TOPIC; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 71149113328     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(09)70228-0     Document Type: Article

References (22)

1. Jabbour E., Issa J.P., Garcia-Manero G., and Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112 (2008) 2341-2351
2. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
3. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
4. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27 (2009) 3842-3848
5. Wijermans P., Suciu S., Baila L., Platzbecker U., Giagounidis A., Selleslag D., et al. Low dose decitabine versus best supportive care in elderly patients with Intermediate or High risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 112 (2008) Abstract 226.
6. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
7. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
8. Fenaux P., Multi G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009) 223-232
9. Qin T., Jelinek J., Si J., Shu J., and Issa J.P. Mechanisms of resistance to 5-aza-2 -deoxycytidine in human cancer cell lines. Blood 113 (2009) 659-667
10. Eisai Pharmaceuticals. Eisai will initiate first head-to-head study comparing Dacogen® (decitabine for injection) and Vidaza® (azacitidine) in patients with myelodysplastic syndromes. Randomized comparator study to evaluate efficacy of commercially available hypomethylating agents, 12/2/2008. Available at: http://www.eisai.com/view_press_release.asp?ID=-1&press=203 Accessed October 5, 2009.
11. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
12. Lyons R.M., Cosgriff T.M., Modi S.S., Gersh R.H., Hainsworth J.D., Cohn A.L., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27 (2009) 1850-1856
13. Kantarjian H., Garcia-Manero G., O'Brien S., Estrov Z., Ravandi F., Cortes J., et al. Survival and efficacy of decitabine in myelodysplastic syndromes (MDS), analysis of the 5-day IV dosing regimen. Blood 110 (2007) Abstract 115.
14. Silverman L.R., McKenzie D.R., Peterson B.L., Odchimar-Reissig R., Hinkle R., Backstrom J.T., et al. Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes (MDS) treated with azacitidine compared with supportive care. Blood 106 (2005) Abstract 2525.
15. Wijermans P.W., Rüter B., Baer M.R., Slack J., Saba H.I., and Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 32 (2008) 587-591
16. Aribi A., Borthakur G., Ravandi F., Shan J., Davisson J., Cortes J., et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109 (2007) 713-717
17. Steensma D.P., and Friday B.B. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leuk Lymphoma 48 (2007) 1628-1629 [Letter].
18. Rüter B., Wijermans P., Claus R., Kunzmann R., and Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110 (2007) 1080-1082 [Letter].
19. Furlan I., Batz C., Flotho C., Mohr B., Lübbert M., Suttorp M., et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 113 (2009) 2867-2868
20. Kantarjian H., Huang X., and Issa J.P. Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule. Blood 110 (2007) 1083
21. Link P.A., Baer M.R., James S.R., Jones D.A., and Karpf A.R. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res 68 (2008) 9358-9366
22. Steensma D.P., Porcher J.C., Litzow M.R., Hogan W.J., Arora S., and Van Laar E.S. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine. Leuk Res 33 (2009) e81-e82 [Letter].